197 related articles for article (PubMed ID: 32167618)
41. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
42. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
Tantai J; Hu D; Yang Y; Geng J
Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
[TBL] [Abstract][Full Text] [Related]
43. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
44. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
Zhang K; Chen L; Deng H; Zou Y; Liu J; Shi H; Xu B; Lu M; Li C; Jiang J; Wang Z
Int J Clin Exp Pathol; 2015; 8(1):629-35. PubMed ID: 25755755
[TBL] [Abstract][Full Text] [Related]
45. Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer.
Liang W; Lv T; Shi X; Liu H; Zhu Q; Zeng J; Yang W; Yin J; Song Y
Medicine (Baltimore); 2016 Sep; 95(37):e4608. PubMed ID: 27631209
[TBL] [Abstract][Full Text] [Related]
46. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
47. Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages.
Chian CF; Hwang YT; Terng HJ; Lee SC; Chao TY; Chang H; Ho CL; Wu YY; Perng WC
Oncotarget; 2016 Aug; 7(31):50582-50595. PubMed ID: 27418131
[TBL] [Abstract][Full Text] [Related]
48. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
[TBL] [Abstract][Full Text] [Related]
49. [OLC1 protein levels in plasma of patients with non-small cell lung cancer and its clinical application].
Yang L; Xiao T; Tan J; Chen S; Gao Y; Cheng S; Liu X; Sun K
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):362-5. PubMed ID: 25030592
[TBL] [Abstract][Full Text] [Related]
50. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C
Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225
[TBL] [Abstract][Full Text] [Related]
51. Serum Fork-Head Box D3 (FOXD3) Expression Is Down-Regulated in and Associated with Diagnosis of Patients with Non-Small Cell Lung Cancer.
Xu BN; Zhang L; Zhang DD; Song CY; Tian DL; Jiang WJ
Med Sci Monit; 2018 Dec; 24():9504-9508. PubMed ID: 30596382
[TBL] [Abstract][Full Text] [Related]
52. Evaluating the diagnostic and prognostic value of serum miR-770 in non-small cell lung cancer.
Sun B; Liu HF; Ding Y; Li Z
Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3061-3066. PubMed ID: 29863251
[TBL] [Abstract][Full Text] [Related]
53. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
[TBL] [Abstract][Full Text] [Related]
54. Serum midkine as non-invasive biomarker for detection and prognosis of non-small cell lung cancer.
Stern L; Mueller E; Bellon E; Reeh M; Grotelueschen R; Guengoer C; Melling N; Goetz M; Perez DR; Izbicki JR; Rawnaq-Möllers T; Ghadban T
Sci Rep; 2021 Jul; 11(1):14616. PubMed ID: 34272441
[TBL] [Abstract][Full Text] [Related]
55. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.
Halvorsen AR; Bjaanæs M; LeBlanc M; Holm AM; Bolstad N; Rubio L; Peñalver JC; Cervera J; Mojarrieta JC; López-Guerrero JA; Brustugun OT; Helland Å
Oncotarget; 2016 Jun; 7(24):37250-37259. PubMed ID: 27191990
[TBL] [Abstract][Full Text] [Related]
56. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
[TBL] [Abstract][Full Text] [Related]
57. Utility of red cell distribution width as a diagnostic and prognostic marker in non-small cell lung cancer.
Song B; Shi P; Xiao J; Song Y; Zeng M; Cao Y; Zhu X
Sci Rep; 2020 Sep; 10(1):15717. PubMed ID: 32973271
[TBL] [Abstract][Full Text] [Related]
58. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
[TBL] [Abstract][Full Text] [Related]
59. Plasma
Wang K; Song X; Li X; Zhang Z; Xie L; Song X
Future Oncol; 2022 Mar; 18(7):821-832. PubMed ID: 34842456
[No Abstract] [Full Text] [Related]
60. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
